Dai Y, Dong C, Wang Z, Zhou Y, Wang Y, Hao Y
Front Immunol. 2025; 15():1482291.
PMID: 39845973
PMC: 11750830.
DOI: 10.3389/fimmu.2024.1482291.
Pellegrini J, Gonzalez-Espinoza G, Shayan R, Hysenaj L, Rouma T, Arce-Gorvel V
Nat Commun. 2025; 16(1):862.
PMID: 39833171
PMC: 11747348.
DOI: 10.1038/s41467-024-55799-2.
Beckers D, Jainarayanan A, Dustin M, Capera J
Immune Netw. 2025; 24(6):e42.
PMID: 39801736
PMC: 11711127.
DOI: 10.4110/in.2024.24.e42.
Lucas S, Thomas S
Mol Pharm. 2024; 21(12):5929-5943.
PMID: 39478434
PMC: 11615947.
DOI: 10.1021/acs.molpharmaceut.4c00692.
Lingel H, Fischer L, Remstedt S, Kuropka B, Philipsen L, Han I
Cell Death Differ. 2024; 32(3):561-572.
PMID: 39390117
PMC: 11893764.
DOI: 10.1038/s41418-024-01399-y.
Mechanical force regulates ligand binding and function of PD-1.
Li K, Cardenas-Lizana P, Lyu J, Kellner A, Li M, Cong P
Nat Commun. 2024; 15(1):8339.
PMID: 39333505
PMC: 11437077.
DOI: 10.1038/s41467-024-52565-2.
Transferrin receptor-targeted immunostimulant for photodynamic immunotherapy against metastatic tumors through -catenin/CREB interruption.
Yan M, Chen X, Li X, Liu Q, Yu B, Cen Y
Acta Pharm Sin B. 2024; 14(9):4118-4133.
PMID: 39309507
PMC: 11413667.
DOI: 10.1016/j.apsb.2024.05.030.
Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade.
Sears T, Pagadala M, Castro A, Lee K, Kong J, Tanaka K
Cancer Immunol Res. 2024; 12(12):1780-1795.
PMID: 39255339
PMC: 11612627.
DOI: 10.1158/2326-6066.CIR-24-0164.
Immune effects of α and β radionuclides in metastatic prostate cancer.
Lunj S, Smith T, Reeves K, Currell F, Honeychurch J, Hoskin P
Nat Rev Urol. 2024; 21(11):651-661.
PMID: 39192074
DOI: 10.1038/s41585-024-00924-5.
Lck Function and Modulation: Immune Cytotoxic Response and Tumor Treatment More Than a Simple Event.
De Sanctis J, Garmendia J, Duchova H, Valentini V, Puskasu A, Kubickova A
Cancers (Basel). 2024; 16(15).
PMID: 39123358
PMC: 11311849.
DOI: 10.3390/cancers16152630.
The combination of tumor mutational burden and T-cell receptor repertoire predicts the response to immunotherapy in patients with advanced non-small cell lung cancer.
Li Y, Ji L, Zhang Y, Zhang J, Reuben A, Zeng H
MedComm (2020). 2024; 5(6):e604.
PMID: 38840771
PMC: 11151154.
DOI: 10.1002/mco2.604.
CD8 T cell-based cancer immunotherapy.
Chen Y, Yu D, Qian H, Shi Y, Tao Z
J Transl Med. 2024; 22(1):394.
PMID: 38685033
PMC: 11057112.
DOI: 10.1186/s12967-024-05134-6.
A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity.
Albu D, Wolf B, Qin Y, Wang X, Daniel Ulumben A, Su M
Oncoimmunology. 2024; 13(1):2316945.
PMID: 38379869
PMC: 10877993.
DOI: 10.1080/2162402X.2024.2316945.
Integrated germline and somatic features reveal divergent immune pathways driving ICB response.
Sears T, Pagadala M, Castro A, Lee K, Kong J, Tanaka K
bioRxiv. 2024; .
PMID: 38293085
PMC: 10827124.
DOI: 10.1101/2024.01.12.575430.
Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs.
Zhao Q, Zong H, Zhu P, Su C, Tang W, Chen Z
Exp Hematol Oncol. 2024; 13(1):6.
PMID: 38254219
PMC: 10802076.
DOI: 10.1186/s40164-024-00474-x.
Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy.
Lee T, Tsai E, Liu S, Hsu Hung S, Chang S, Chao C
Cancer Res. 2024; 84(6):800-807.
PMID: 38231470
PMC: 10940856.
DOI: 10.1158/0008-5472.CAN-23-2664.
Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy.
Li T, Wang X, Niu M, Wang M, Zhou J, Wu K
Front Immunol. 2023; 14:1196970.
PMID: 37520520
PMC: 10373067.
DOI: 10.3389/fimmu.2023.1196970.
Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer.
Wang L, Yang Z, Guo F, Chen Y, Wei J, Dai X
Front Immunol. 2023; 14:1227797.
PMID: 37465684
PMC: 10351040.
DOI: 10.3389/fimmu.2023.1227797.
What's the Catch? The Significance of Catch Bonds in T Cell Activation.
Faust M, Rase V, Lamb T, Evavold B
J Immunol. 2023; 211(3):333-342.
PMID: 37459191
PMC: 10732538.
DOI: 10.4049/jimmunol.2300141.
Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer.
Hu C, Liu M, Li Y, Zhao Y, Sharma A, Liu H
Front Immunol. 2023; 14:1213716.
PMID: 37457699
PMC: 10346844.
DOI: 10.3389/fimmu.2023.1213716.